EICHORPublic-registry site landscape for NCT07693777, “A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia”, a Severe Hypertriglyceridemia (sHTG) study sponsored by Zhejiang Doer Biologics Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07693777 (registry record) |
| Study title | A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of DR10624 in Subjects With Severe Hypertriglyceridemia Receiving Stable Lipid-Modifying Therapy |
| Sponsor | Zhejiang Doer Biologics Co., Ltd. |
| Condition(s) | Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia |
| Phase | PHASE3 |
| Listed sites | 1 |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07693777.
Eichor generates a preliminary site-risk snapshot for NCT07693777 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Severe Hypertriglyceridemia (sHTG) trials
More from Zhejiang Doer Biologics Co., Ltd.
← Eichor home · All tracked trials · Severe Hypertriglyceridemia (sHTG) studies · Weekly briefs
